Patient-specific neoantigen-HLA complex (NeoAg-HLA)

Patient-specific neoantigen-HLA complexes are unique molecular targets formed when mutated proteins in tumor cells are processed and presented on the cell surface by Human Leukocyte Antigen (HLA) molecules (Nature, 2017). These neoantigens arise from somatic mutations—such as single nucleotide variants, insertions, or deletions—that are unique to an individual's tumor, ensuring they are not expressed in healthy tissues (Science, 2017). Because they are recognized as non-self by the immune system, they are highly immunogenic and bypass central thymic tolerance, making them ideal targets for precision immunotherapy (NEJM, 2017). Therapeutic strategies targeting these complexes include personalized mRNA or peptide vaccines and adoptive T-cell therapies using engineered T-cell receptors (TCRs) (Frontiers in Immunology, 2021). These treatments aim to prime or expand cytotoxic T-cell populations that specifically recognize and eliminate cells displaying the neoantigen-HLA complex. Despite their potential, challenges include the high cost of personalized manufacturing, the complexity of accurately predicting which mutations will be presented, and the risk of tumor escape through HLA downregulation (Nature Reviews Cancer, 2021).

Other names

Tumor-specific neoantigen (TSNA)Neoepitope-HLA complexPersonalized neoantigenMutated self-antigenNeoantigen-MHC complexTumor-specific antigen (TSA)

Induction of antigen-specific cytotoxic T-lymphocyte (CTL) response via T-cell receptor (TCR) recognition of the peptide-HLA complex.